Umbralisib

Umbralisib is an experimental oral PI3K delta inhibitor (previously known as RP5264 and TGR 1202).[1]

It has had clinical studies for Chronic lymphocytic leukemia (CLL).[2][3]

Three year data (including Follicular lymphoma and DLBCL) was announced June 2016.[4]

It is in combination trials for various leukemias and lymphomas, eg Mantle cell lymphoma (MCL).[5][6]

References

  1. ↑ "Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies". clinicaltrials.gov.
  2. ↑ Novel BTK, PI3K Inhibitors on Horizon for Relapsed CLL. March 2016
  3. ↑ Therapy Focus - TG Could Benefit From Zydelig Setback. March 2016
  4. ↑ TG Therapeutics Inc.: TG Therapeutics, Inc. Announces First Patient Enrolled in the Registration-Directed UNITY-DLBCL Phase 2b Trial. June 2016
  5. ↑ A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
  6. ↑ Follow-Up Data for Combination of TGR-1202 (umbralisib) plus Ibrutinib in Patients with Relapsed or Refractory CLL and MCL. 2017
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.